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Abstract: 18F-FDG PET/CT is increasingly applied in staging and response to treatment assessment of lymphomas. 
Multiple isolated cases with extranodal involvement of Non hodgkins Lymphoma (NHL), detected on 18F-FDG PET/CT, 
have been previously reported. Here, we report a rare case of extranodal NHL involving multiple sites namely 
pericardium, kidney, pancreas in addition to mediastinal lymph nodes which were detected on 18F- FDG PET/CT.In the 
present case, involvement was accurately demonstrated, and early complete remission was documented using baseline 
and follow-up FDG PET/CT. 
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INTRODUCTION 
Diffuse large B cell Lymphoma (DLBCL) is the most 
common type of Non hodgkins Lymphoma (NHL) 
constituting 33%of all cases. The patient can present 
either with a primary disease of lymph nodes or that of 
extranodal sites. More than half of the patients have 
some site of extranodal involvement at the time of initial 
diagnosis. Any organ can be involved, with the most 
common sites being the gastrointestinal tract and bone 
marrow, each being involved in 15-20 % of the patients 
[1].
 
pericardium, pancreas and renal involvement is 
quite uncommon in DLBCL [2].
 
Uncovering such rare 
sites in one single patient highlights the role of whole 
body 18F Fluorodeoxyglucose(FDG) Positron Emission 
Tomography/Computed Tomography (18F-FDG 
PET/CT) in staging of lymphomas. Also, it serves as a 
baseline, which can be compared to the post-treatment 
study for assessing response, as in this case, wherein 
a post-treatment PET/CT study shows complete 
metabolic response to treatment. 
CASE REPORT 
A 55-years old man, presented with history of 
unexplained fever, weight loss and Chest discomfort .X 
ray chest revealed anterior mediastinal mass lesion. A 
biopsy from the mediastinal mass confirmed it to be 
NHL B cell type. Patient was then referred for a 
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Maximum intensity projection (MIP) images (Figure 1a) 
revealed multiple foci of increased tracer uptake in 
mediastinal and abdominal regions. In addition, there 
were two foci of intense uptake on the left side of 
abdomen. Axial fused PET/CT images revealed uptake 
to anterior mediastinal mass (Figure 1b), pericardium 
(Figure 1c), body of pancreas and left kidney (Figure 
1d). Patient received four cycles of intravenous bolus 
 
Figure 1: Whole body fluorodeoxyglucose-positron emission 
tomography/computed tomography (PET/CT) maximum 
intensity projection image (a) showing abnormal tracer foci in 
mediastinum and two foci in abdomen on left side (arrow and 
arrowhead), Axial fused PET/CT showed a intense uptake in 
the anterior mediastinal lesion (b), pericardium lesions 
(arrow) (c), pancreas and left kidney lesions (arrows)(d). 
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chemotherapy regimen, R-CHOP (Rituximab with 
cyclophosphamide, doxorubicin, vincristine and 
prednisone) after which he was referred for a FDG 
PET/CT study for treatment response assessment. 
Post-treatment FDG PET/CT study revealed no 
abnormal focus of FDG uptake in the entire body, 
suggestive of complete metabolic and morphological 
response to treatment in pericardium, pancreas and left 
kidney (Figure 2). 
 
Figure 2: Post treatment Whole body fluorodeoxyglucose-
positron emission tomography/computed tomography 
(PET/CT) maximum intensity projection image showing no 
abnormal uptake suggesting complete metabolic response to 
therapy. 
DISCUSSION 
DLBCL can involve various extranodal sites such as 
the gastrointestinal tract, bone, brain, testis, ovary, 
lung, nasopharynx, soft tissue, thyroid, kidney, liver, 
breast, skin, etc [3]. Heart and pericardium are rarely 
involved in DLBCL. The involvement is usually 
revealed by cardiac complications and is associated 
with a poor prognosis. Julian et al. reported two cases 
of DLBCL with cardiac involvement (apical septum, 
right ventricle and right auricle) detected by 18F-FDG 
that allowed an early diagnosis and chemotherapy, 
therefore, improving the survival [4]. Few cases of 
cardiac involvement in DLBCL have been reported, 
both primary and metastatic, detected by 18F-FDG [5, 
6].
 
In our case multiple separate nodular lesions were 
detected in pericardium. 
Renal involvement in most of the cases it is 
secondary and occurs by hematogenous spread or by 
direct extension of the disease from a retroperitoneal 
mass [7]. As FDG is excreted by the kidneys, it can 
lead to false positive and false negative interpretations 
on 18F-FDG. Renal involvement in NHL is seen as 
multiple focal areas of increased FDG uptake mostly in 
renal cortices that may be unilateral or less commonly, 
bilateral. There may or may not be corresponding 
lesions in non diagnostic CT scans [8]. In the present 
case, single focal area of increased radiotracer uptake 
was noted in left renal cortex. This lesion was isodense 
and non-enhancing on Contrast Enhanced CT. 
Pancreatic involvement may be diffuse (resembling 
pancreatitis) in the form of focal masses or as 
secondary involvement from adjacent lymph nodes. 
Secondary pancreatic involvement has been reported 
in only 0.2-2% of patients with NHL [9, 10].
 
Therefore, whole body imaging with a sensitive 
modality such as 18F-FDG is mandatory to assess the 
extent of disease by detecting unexpected extranodal 
sites of disease or exclusion of disease in the presence 
of nonspecific extranodal CT findings [11]. In patients 
with known disease, other goals can be accomplished, 
which are evaluation of response to therapy (complete 
response was demonstrated in the present case), 
identification of new or recurrent disease, and 
monitoring the complications of therapy. In patients, 
where the disease has not been confirmed, imaging 
helps in reaching a provisional diagnosis .In 
conclusion, the present case highlights the utility of 
18F-FDG in detection of extranodal NHL at 
unsuspected sites which may have an important 
bearing on the management and prognosis. 
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